An expert hematologist/oncologist will highlight the traditional treatment options, unmet needs, and recent advances and approvals in chronic graft vs host disease. Clinical trials will be described as well as novel agents on the horizon.
EP. 1: An Overview of the Graft vs Host Disease Landscape
Corey Cutler, MD, MPH, FRCPC, provides an overview of graft vs host disease and some of the factors that may put patients at higher risk.
EP. 2: Prophylactic Strategies in Graft vs Host Disease Management
Expert insight on prophylaxis in graft vs host disease, with a focus on specific pharmacologics and the overall efficacy of prophylactic strategies.
EP. 3: An Overview of Treatment Options for Chronic GVHD
A comprehensive review of the treatment armamentarium for patients with chronic graft vs host disease.
EP. 4: REACH-2 Trial of Ruxolitinib in Steroid-Refractory Acute GVHD
Corey Cutler, MD, MPH, FRCPC, reviews the study design and results of REACH-2, which tested ruxolitinib in patients with steroid-refractory acute GVHD.
EP. 5: REACH-3 Trial of Ruxolitinib in Steroid-Refractory Chronic GVHD
Expert insight on the study design and results of REACH-3, which tested ruxolitinib in patients with steroid-refractory chronic GVHD.
EP. 6: The Evolving Treatment Landscape of Chronic GVHD
Closing out his discussion on chronic GVHD, Corey Cutler, MD, MPH, FRCPC, discusses belumosudil and how all 3 newly approved agents fit into the evolving treatment landscape.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.